Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features
Open Access
- 11 February 2010
- journal article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 12 (1), R12
- https://doi.org/10.1186/bcr2478
Abstract
Most breast cancers that occur in women with germline BRCA1 mutations are estrogen receptor-negative (ER-) and also typically lack expression of progesterone receptor (PR) and HER2 overexpression. We undertook a study to assess the clinical factors that predict for an estrogen receptor positive (ER+) breast cancer in BRCA1 mutation carriers and to characterize the pathologic features of these tumors.This publication has 29 references indexed in Scilit:
- Getting to the Root of BRCA1-Deficient Breast CancerCell Stem Cell, 2009
- Aromatase expression is increased in BRCA1mutation carriersBMC Cancer, 2009
- Altered Proliferation and Differentiation Properties of Primary Mammary Epithelial Cells from BRCA1 Mutation CarriersCancer Research, 2009
- High Frequency of TP53 Mutation in BRCA1 and Sporadic Basal-like Carcinomas but not in BRCA1 Luminal Breast TumorsCancer Research, 2009
- BRCA1 regulates human mammary stem/progenitor cell fateProceedings of the National Academy of Sciences of the United States of America, 2008
- Heterogenic Loss of the Wild-Type BRCA Allele in Human Breast TumorigenesisAnnals of Surgical Oncology, 2007
- BRCA1 Haploinsufficiency, but not Heterozygosity for a BRCA1-truncating Mutation, Deregulates Homologous RecombinationCell Cycle, 2007
- Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast CancerJNCI Journal of the National Cancer Institute, 2003
- HER‐2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer RegistryCancer, 2002
- Tumour biological features of BRCA1-induced breast and ovarian cancerEuropean Journal of Cancer, 1997